Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival - Results from the do tirofiban and ReoPro give similar efficacy outcome trial (TARGET)

被引:83
作者
Chan, AW
Moliterno, DJ
Berger, PB
Stone, GW
DiBattiste, PM
Yakubov, SL
Sapp, SK
Wolski, K
Bhatt, DL
Topol, EJ
机构
[1] Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA
[2] Alton Ochsner Med Fdn & Ochsner Clin, Dept Cardiol, New Orleans, LA 70121 USA
[3] Mayo Clin & Mayo Fdn, Div Cardiol, Rochdale, MN USA
[4] Lenox Hill Heart & Vasc Inst, New York, NY USA
[5] Merck, W Point, PA USA
[6] Riverside Methodist Hosp, Columbus, OH 43214 USA
[7] Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA
关键词
D O I
10.1016/S0735-1097(03)00944-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES We sought to examine if clopidogrel treatment initiated before coronary stenting improved clinical outcomes among patients receiving aspirin and a glycoprotein (GP) IIb/IIIa inhibitor. BACKGROUND Antiplatelet therapy plays a pivotal role in contemporary percutaneous coronary interventions (PCI). METHODS Outcomes among 4,809 patients randomized to tirofiban or abciximab during PCI with stent placement were compared according to whether they received 300 mg of clopidogrel before PCI (93.1%) versus immediately after the procedure. RESULTS The 30-day primary composite end point (death, myocardial infarction [MI], or urgent target vessel revascularization [TVR]) was lower among clopidogrel-pretreated patients (6.6% vs. 10.4%, p = 0.009), mainly because of reduction of MI (6.0% vs. 9.5%, p = 0.012). The benefit of clopidogrel pretreatment was sustained at six months (death, MI, any TVR: 14.6% vs. 19.8%, HR = 0.71, p = 0.010), and this was due mainly to lowering of death and MI (7.8% vs. 13.0%, p = 0.001). At one year, clopidogrel pretreatment was associated with a lower mortality rate (1.7% vs. 3.6%, p = 0.011). Because clopidogrel pretreatment was not randomized, multivariable and propensity analyses were performed. After adjusting for baseline heterogeneity, clopidogrel pretreatment was an independent predictor for death or MI at 30 days (HR = 0.63, p = 0.012) and at six months (HR = 0.61, p = 0.003), and survival at one year (HR = 0.53, p = 0.044). No excess in 30-day bleeding events was noted with clopidogrel pretreatment. CONCLUSIONS Among patients undergoing coronary stent placement with aspirin and a GP IIb/IIIa inhibitor, clopidogrel pretreatment is associated with a reduction of death and MI irrespective of the type of GP IIb/IIIa inhibitor used. (C) 2003 by the American College of Cardiology Foundation.
引用
收藏
页码:1188 / 1195
页数:8
相关论文
共 49 条
[1]   Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban) [J].
Assali, AR ;
Salloum, J ;
Sdringola, S ;
Moustapha, A ;
Ghani, M ;
Hale, S ;
Schroth, G ;
Fujise, K ;
Anderson, HV ;
Smalling, RW ;
Rosales, OR .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (08) :884-+
[2]   ASPIRIN AND DIPYRIDAMOLE IN THE PREVENTION OF ACUTE CORONARY-THROMBOSIS COMPLICATING CORONARY ANGIOPLASTY [J].
BARNATHAN, ES ;
SCHWARTZ, JS ;
TAYLOR, L ;
LASKEY, WK ;
KLEAVELAND, JP ;
KUSSMAUL, WG ;
HIRSHFELD, JW .
CIRCULATION, 1987, 76 (01) :125-134
[3]   Safety and efficacy of only 2 weeks of ticlopidine therapy in patients at increased risk of coronary stent thrombosis: Results from the Antiplatelet Therapy alone versus Lovenox plus Antiplatelet therapy in patients at increased risk of Stent Thrombosis (ATLAST) trial [J].
Berger, PB ;
Mahaffey, KW ;
Meier, SJ ;
Buller, CE ;
Batchelor, W ;
Fry, ETA ;
Zidar, JP .
AMERICAN HEART JOURNAL, 2002, 143 (05) :841-846
[4]   Clopidogrel versus ticlopidine after intracoronary stent placement [J].
Berger, PB ;
Bell, MR ;
Rihal, CS ;
Ting, H ;
Barsness, G ;
Garratt, K ;
Bellot, V ;
Mathew, V ;
Melby, S ;
Hammes, L ;
Grill, D ;
Holmes, DR .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1999, 34 (07) :1891-1894
[5]   Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting - The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS) [J].
Bertrand, ME ;
Rupprecht, HJ ;
Urban, P ;
Gershlick, AH .
CIRCULATION, 2000, 102 (06) :624-629
[6]   Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting [J].
Bhatt, DL ;
Bertrand, ME ;
Berger, PB ;
L'Allier, PL ;
Moussa, I ;
Moses, JW ;
Dangas, G ;
Taniuchi, M ;
Lasala, JM ;
Holmes, DR ;
Ellis, SG ;
Topol, EJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (01) :9-14
[7]   Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans [J].
Cadroy, Y ;
Bossavy, JP ;
Thalamas, C ;
Sagnard, L ;
Sakariassen, K ;
Boneu, B .
CIRCULATION, 2000, 101 (24) :2823-2828
[8]   Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein [J].
Chew, DP ;
Bhatt, DL ;
Robbins, MA ;
Mukherjee, D ;
Roffi, M ;
Schneider, JP ;
Topol, EJ ;
Ellis, SG .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (06) :672-674
[9]   Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention [J].
Chew, DP ;
Bhatt, DL ;
Robbins, MA ;
Penn, MS ;
Schneider, JP ;
Lauer, MS ;
Topol, EJ ;
Ellis, SG .
CIRCULATION, 2001, 104 (09) :992-997
[10]  
Cutlip DE, 2001, CIRCULATION, V103, P1967